전체 프로그램

ADCLimited DatastaleDaiichi Sankyo Co., Ltd.Phase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+3

Trials 149Status Recruiting

ADCLimited DatastaleDaiichi Sankyo Co., Ltd.deruxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Avelumab (Avelumab)

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Mabthera (Mabthera)

Camrelizumab (Camrelizumab)

Panitumumab (Panitumumab)

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Ramucirumab (Ramucirumab)

Blinatumomab (Blinatumomab)

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103)

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

Denosumab (Denosumab)

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

nivolumab (Opdivo, ipilimumab + nivolumab)

전체 프로그램

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Avelumab (Avelumab)

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Mabthera (Mabthera)

Camrelizumab (Camrelizumab)

Panitumumab (Panitumumab)

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Ramucirumab (Ramucirumab)

Blinatumomab (Blinatumomab)

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103)

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

Denosumab (Denosumab)

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

nivolumab (Opdivo, ipilimumab + nivolumab)

전체 프로그램

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Avelumab (Avelumab)

Anti-B Cell Maturation Antigen (BCMA, Anti-B Cell Maturation Antigen, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells)

Mabthera (Mabthera)

Camrelizumab (Camrelizumab)

Panitumumab (Panitumumab)

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Ramucirumab (Ramucirumab)

Blinatumomab (Blinatumomab)

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell, Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103)

Anti-CD19 CAR T-cells (Anti-CD19 CAR T-cells)

Denosumab (Denosumab)

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

nivolumab OR pembrolizumab (glembatumumab vedotin and PD-1 targeted checkpoint inhibitor, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab))

nivolumab (Opdivo, ipilimumab + nivolumab)